DOCSLIB.ORG

Phd Thesis Nancy Tuchscheerer FINAL 1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Phd Thesis Nancy Tuchscheerer FINAL 1 “The Ligands of CXCR4 in Vascularization” Von der Fakultät für Mathematik, Informatik und Naturwissenschaften der RWTH Aachen University zur Erlangung des akademischen Grades einer Doktorin der Naturwissenschaften genehmigte Dissertation vorgelegt von Diplom-Trophologin Nancy Tuchscheerer aus Zwenkau, Deutschland Berichter: Universitätsprofessor Dr.rer.nat. Jürgen Bernhagen Universitätsprofessor Dr.techn. Werner Baumgartner Tag der mündlichen Prüfung: 14. Juni 2012 Die Dissertation ist auf den Internetseiten der Hochschulbibliothek online Verfügbar. The results of this work were in part published in: Liehn, E.A.*, N. Tuchscheerer *, I. Kanzler, M. Drechsler, L. Fraemohs, A. Schuh, R.R. Koenen, S. Zander, O. Soehnlein, M. Hristov, G. Grigorescu, A.O. Urs, M. Leabu, I. Bucur, M.W. Merx, A. Zernecke, J. Ehling, F. Gremse, T. Lammers, F. Kiessling, J. Bernhagen, A. Schober, and C. Weber. 2011. Double-edged role of the CXCL12/CXCR4 axis in experimental myocardial infarction. J Am Coll Cardiol . 58:2415-2423 Isabella Kanzler*, Nancy Tuchscheerer *, Sakine Simsekyilmaz, Simone Konschalla, Andreas Kroh, Guy Steffens, Andreas Schober, Christian Weber, Jürgen Bernhagen, Elisa A. Liehn. 2011. Macrophage migration inhibitory factor plays a pivotal role in EPCs-induced angiogenesis. Circ. Res. submitted . N. Tuchscheerer *, I. Kanzler*, Mark Vries, A. Wagenaar, E. Liehn, D.G.M. Molin, J. Bernhagen*, M.J. Post*. 2011. Macrophage migration inhibitory factor, a CXCR ligand with a function in arteriogenesis. Circ. Res. in preparation. TABLE OF CONTENTS Table of Contents TABLE OF CONTENTS ............................................................................................. I ABBREVIATIONS ...................................................................................................... V I INTRODUCTION .................................................................................................. 1 I.1 Cardiovascular Diseases, Myocardial Infarction, and Peripheral Artery Disease ........................................................................................................ 1 I.2 Angiogenesis and Arteriogenesis, Two Forms of Vascularization ............... 2 I.2.1 Angiogenesis ..................................................................................... 2 Mechanisms of Angiogenesis ....................................................... 3 Angiogenesis in Hypoxic Conditions ............................................. 4 Murine Myocardial Infarction Model, a Model of Angiogenesis ..... 6 The Role of Endothelial Progenitor Cells ...................................... 7 Endothelial Progenitor Cells in Angiogenesis and Vascular Repair ........................................................................................... 8 I.2.2 Arteriogenesis ................................................................................... 9 Stages of Arteriogenesis ............................................................. 11 The Role of Monocytes/Macrophages in Arteriogenesis ............. 12 Hindlimb Ischemia Model, a Model of Arteriogenesis.................. 16 I.2.3 Angiogenesis vs. Arteriogenesis ..................................................... 17 I.3 Cytokines and Chemokines ....................................................................... 18 I.3.1 Receptor / Ligand Interactions in Monocyte Recruitment ................ 20 I.3.2 CXCR4: Structure, Functions and Ligands ...................................... 21 Stromal Cell-derived Factor-1, CXCL12 ...................................... 21 The CXCL12 / CXCR4 Axis in Myocardial Infarction ................... 22 Macrophage Migration Inhibitory Factor ...................................... 23 I.3.3 The Role of Chemokines and Cytokines in Myocardial Infarction and Peripheral Artery Disease......................................................... 27 I.3.4 The Role of Chemokines and Cytokines in Endothelial Progenitor Cells Function.................................................................................. 28 II AIM OF THE STUDY ......................................................................................... 30 I TABLE OF CONTENTS III MATERIAL AND METHODS ............................................................................. 31 III.1 General Equipment .................................................................................... 31 III.2 General Solutions, Media and Buffers ....................................................... 32 III.3 Chemokines/Cytokines and Recombinant Proteins ................................... 33 III.4 Antibodies .................................................................................................. 34 III.4.1 Primary Antibodies .......................................................................... 34 III.4.2 Isotype Controls .............................................................................. 34 III.4.3 Secondary Antibodies ..................................................................... 34 III.4.4 Directly Conjugated Antibodies ....................................................... 34 III.4.5 Blocking Antibodies ......................................................................... 35 III.5 Mice ........................................................................................................... 35 III.6 Cell culture and Cell Isolation .................................................................... 36 III.6.1 Cell Culturing of WEHIs and SVECs ............................................... 36 III.6.2 Isolation of Angiogenic Early Outgrowth EPCs ............................... 36 III.6.3 Cardiomyocyte Isolation and Hypoxia Experiments ........................ 37 III.6.4 Isolation of Blood Monocytes .......................................................... 37 III.6.5 Isolation of Bone Marrow-Derived Monocytes ................................. 37 III.7 Biomolecular Methods ............................................................................... 38 III.7.1 mRNA Isolation and Reverse Transcription - Polymerase Chain Reaction .......................................................................................... 38 III.7.2 Quantification of RNA and Quantitative Real-Time Polymerase Chain Reaction .......................................................................................... 39 III.8 Protein Assays ........................................................................................... 41 III.8.1 Flow Cytometry Analysis ................................................................. 41 III.8.2 Histochemistry and Immunohistochemistry ..................................... 42 Histomorphometry and Determination of Myocardial Infarction Size ............................................................................. 42 Cellular Stainings of Inflammatory Cells in the Heart .................. 43 Cellular Stainings of Receptors and MIF in Hindlimb Tissue ....... 43 III.8.3 AcLDL and Lectin Uptake ................................................................ 44 III.9 Functional Assays ...................................................................................... 44 III.9.1 Chemotaxis Assay ........................................................................... 44 III.9.2 Transmigration Assay ...................................................................... 44 III.9.3 Static Cell Adhesion Assay ............................................................. 45 II TABLE OF CONTENTS III.9.4 Flow Cell Adhesion Assay ............................................................... 45 III.9.5 Matrigel Assay in vitro ..................................................................... 46 III.9.6 Electron Microscopy ........................................................................ 46 III.9.7 Lipid Extraction and HPLC .............................................................. 46 III.9.8 Gas-Chromatography of Fatty Acids ............................................... 47 III.10 Animal Experiments ................................................................................... 47 III.10.1 Murine Model of Myocardial Infarction ............................................. 47 III.10.2 Bone Marrow Reconstitution ........................................................... 48 III.10.3 Ultrasound Analysis ......................................................................... 48 III.10.4 Langendorff Perfusion ..................................................................... 48 III.10.5 Vessel Density (High-Resolution Computer Tomography) .............. 49 III.10.6 Ischemia Hindlimb Model ................................................................ 49 III.10.7 Pre- and Post Laser Doppler Measurements .................................. 50 III.11 Statistical Analysis ..................................................................................... 51 IV RESULTS .......................................................................................................... 5251 IV.1 The Role of the CXCL12 / CXCR4 Axis in Experimental Myocardial Infarction .................................................................................................... 52 IV.1.1 Analysis of MI Size and Inflammatory Cell Content ......................... 52 IV.1.2 Analysis of Cardiac Function after MI .............................................. 55 IV.1.3 The Role of CXCR4 for EPC Trafficking and Function .................... 60 IV.1.4 Myocardial Apoptosis after Myocardial Infarction ............................ 62 IV.1.5 Electron Microscopy
Load more

Recommended publications
  • An Update on Pathophysiology and Medical Management of Endometriosis
    Advances in Reproductive Sciences, 2016, 4, 53-73 Published Online May 2016 in SciRes. http://www.scirp.org/journal/arsci http://dx.doi.org/10.4236/arsci.2016.42008 An Update on Pathophysiology and Medical Management of Endometriosis Kulvinder Kochar Kaur1, Gautam Allahbadia2 1Department of Obstetrics and Gynaecology (Reproductive Neuroendocrinology and Infertility), Dr. Kulvinder Kaur Centre for Human Reproduction, Jalandhar, India 2Rotunda—A Centre for Human Reproduction, Mumbai, India Received 24 February 2016; accepted 21 May 2016; published 24 May 2016 Copyright © 2016 by authors and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/ Abstract Endometriosis is an inflammatory oestrogen dependent disease defined by the presence of endo- metrial glands and stroma at extrauterine sites. The modern advance in treatment of endometri- osis management is tackling the debilitating pain it causes, besides the infertility in patients de- siring fertility in reproductive age group. This can be achieved by surgical or medical means, al- though in most cases a combination of both treatments is required. Usually, long term treatment is required in most cases. Unfortunately in most cases, pain symptoms recur between 6months and 12 months once treatment is stopped. A lot of research has gone in understanding the pathogene- sis and further medical management of endometriosis besides surgery to be useful in relieving pain and use
    [Show full text]
  • Why Are Tumour Blood Vessels Abnormal and Why Is It Important to Know?
    British Journal of Cancer (2009) 100, 865 – 869 & 2009 Cancer Research UK All rights reserved 0007 – 0920/09 $32.00 www.bjcancer.com Minireview Why are tumour blood vessels abnormal and why is it important to know? 1,2 1,2 1,2 ,1,2 JA Nagy , S-H Chang , AM Dvorak and HF Dvorak* 1Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA; 2Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA Tumour blood vessels differ from their normal counterparts for reasons that have received little attention. We report here that they are of at least six distinct types, we describe how each forms, and, looking forward, encourage the targeting of tumour vessel subsets that have lost their vascular endothelial growth factor-A (VEGF-A) dependency and so are likely unresponsive to anti-VEGF-A therapies. British Journal of Cancer (2009) 100, 865–869. doi:10.1038/sj.bjc.6604929 www.bjcancer.com Published online 24 February 2009 & 2009 Cancer Research UK Keywords: angiogenesis; arteriogenesis; venogenesis; tumour blood vessels; VEGF-A It has been known for more than a century that tumours have their respects do they differ from normal blood vessels? How do tumour own blood supply and that, for the better part of that time, the vessels form? Why are they abnormal? And, finally, why might an tumour vasculature is highly abnormal. At one time it was thought understanding of tumour blood vessel diversity be important that the tumour vasculature was actually superior to that of normal clinically? Hopefully, addressing these questions will clarify some tissues; this misconception arose because tumour vessels are often of the mechanisms by which tumours induce their abnormal blood of large size and were, therefore, more conspicuous than the vessels and lead to the development of therapies that more smaller, more numerous and functionally more effective blood effectively target them.
    [Show full text]
  • Mechanisms of Angiogenesis and Arteriogenesis
    © 2000 Nature America Inc. • http://medicine.nature.com REVIEW Endothelial and smooth muscle cells interact with each other to form new blood vessels. In this review, the cellular and molecular mechanisms underlying the formation of endothelium-lined channels (angiogenesis) and their maturation via recruitment of smooth muscle cells (arteriogenesis) during physiological and pathological conditions are summarized, alongside with possible therapeutic applications. Mechanisms of angiogenesis and arteriogenesis Normal tissue function depends on ade- sels in diabetic patients causes aneurys- quate supply of oxygen through blood PETER CARMELIET mal dilatation, bleeding and blindness. vessels. Understanding how blood ves- During the subsequent arteriogenesis, sels form has become a principal, yet challenging, objective of vessels become covered by a muscular coat, thereby endowing the last decade. Unraveling these mechanisms would offer blood vessels with viscoelastic and vasomotor properties, nec- therapeutic options to ameliorate or perhaps even cure disor- essary to accommodate the changing needs in tissue perfusion ders that are now leading causes of mortality. In this mille- (Fig. 1). Periendothelial cells also assist endothelial cells in ac- nium, we will be required to answer such questions as: Will it quiring specialized functions in different vascular beds3. be possible to treat ischemic heart disease by stimulating my- Arteriogenesis is recapitulated during the pathological enlarge- ocardial angiogenesis, and will it be feasible to cure cancer or ment of preexisting collateral vessels (Fig. 2). Therefore, strate- inflammatory disorders by suppressing excessive vessel gies to promote sustainable and functional new blood vessels growth? Unfortunately, research on angiogenesis has for too should not be restricted to the induction of capillary angio- long remained descriptive, mainly because the molecular ‘play- genesis, but should include the stimulation of arteriogenesis.
    [Show full text]
  • Molecular Mechanisms Associated with ROS-Dependent Angiogenesis in Lower Extremity Artery Disease
    antioxidants Review Molecular Mechanisms Associated with ROS-Dependent Angiogenesis in Lower Extremity Artery Disease Greg Hutchings 1,2,†, Łukasz Kruszyna 3,† , Mariusz J. Nawrocki 2 , Ewa Strauss 3,4 , Rut Bryl 2 , Julia Spaczy ´nska 2, Bartłomiej Perek 5 , Marek Jemielity 5, Paul Mozdziak 6,7 , Bartosz Kempisty 2,7,8,9,*, Michał Nowicki 7 and Zbigniew Krasi ´nski 3 1 The School of Medicine, Medical Sciences and Nutrition, Aberdeen University, Aberdeen AB25 2ZD, UK; [email protected] 2 Department of Anatomy, Poznan University of Medical Sciences, 60-781 Poznan, Poland; [email protected] (M.J.N.); [email protected] (R.B.); [email protected] (J.S.) 3 Department of Vascular and Endovascular Surgery, Angiology and Phlebology, Poznan University of Medical Sciences, 60-848 Poznan, Poland; [email protected] (Ł.K.); [email protected] (E.S.); [email protected] (Z.K.) 4 Institute of Human Genetics, Polish Academy of Sciences, 60-479 Poznan, Poland 5 Department of Cardiac Surgery and Transplantology, Poznan University of Medical Sciences, 61-848 Poznan, Poland; [email protected] (B.P.); [email protected] (M.J.) 6 Physiology Graduate Program, North Carolina State University, Raleigh, NC 27695, USA; [email protected] 7 Prestage Department of Poultry Science, North Carolina State University, Raleigh, NC 27695, USA; [email protected] 8 Department of Histology and Embryology, Poznan University of Medical Sciences, 60-781 Poznan, Poland 9 Citation: Hutchings, G.; Kruszyna, Department of Veterinary Surgery, Institute of Veterinary Medicine, Nicolaus Copernicus University in Toru´n, Ł.; Nawrocki, M.J.; Strauss, E.; Bryl, 87-100 Toru´n,Poland * Correspondence: [email protected] R.; Spaczy´nska,J.; Perek, B.; Jemielity, † Both authors equally contributed to the work.
    [Show full text]
  • Inflammatory Monocyte Response Due to Altered Wall Shear Stress in an Isolated Femoral Artery Model Aparna A
    Journal of Biological Methods | 2019 | Vol. 6(1) | e109 DOI: 10.14440/jbm.2019.274 ARTICLE Inflammatory monocyte response due to altered wall shear stress in an isolated femoral artery model Aparna A. Kadam1, Robert P. Gersch2, Todd K. Rosengart3*, Mary D. Frame1* 1Department of Biomedical Engineering, Physiology and Biophysics, Stony Brook University, Stony Brook, NY 11794-5281, USA 2Department of Surgery, Stony Brook University, Stony Brook, NY 11794-5281, USA 3Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA *Corresponding authors: Mary D. Frame, Email: [email protected]; Todd K. Rosengart, Email: [email protected] Competing interests: The authors have declared that no competing interests exist. Abbreviations used: DMEM, dulbecco’s modified eagle medium; Egr, early growth response; eNOS, endothelial nitric oxide synthase; FAE, femoral artery excision; FBS, fetal bovine serum; FGF, fibroblast growth factor; GMCSF, granulocyte macrophage colony-stimulating factor; hpf, high-powered field; ICAM, intracellular adhesion molecule; IL, inter- leukin; IPA, isopropyl alcohol; MCP, monocyte chemoattractant protein; MMP, matrix metalloproteinases; pWSS, physiological wall shear stress; qPCR, quantitative polymerase chain reaction; RPM, revolutions per minute; TGF, transforming growth factor; TNF, tumor necrosis factor; VCAM, vascular cell adhesion molecule; VEGF, vascular endothelial growth factor; VSMC, vascular smooth muscle cell; WSS, wall shear stress Received September 18, 2018; Revision received November 12, 2018; Accepted November 28, 2018; Published February 20, 2019 ABSTRACT Arteriogenesis (collateral formation) is accompanied by a pro-inflammatory state that may be related to the wall shear stress (WSS) within the neo-collateral vessels. Examining the pro-inflammatory componentin situ or in vivo is complex.
    [Show full text]
  • Arteriogenesis – Molecular Regulation, Pathophysiology and Therapeutics I
    Elisabeth Deindl, Wolfgang Schaper (Editors) Arteriogenesis – Molecular Regulation, Pathophysiology and Therapeutics I Shaker Verlag Aachen 2011 Bibliographic information published by the Deutsche Nationalbibliothek The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available in the Internet at http://dnb.d-nb.de. Copyright Shaker Verlag 2011 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publishers. Printed in Germany. ISBN 978-3-8322-9797-8 ISSN 0945-0890 Shaker Verlag GmbH • P.O. BOX 101818 • D-52018 Aachen Phone: 0049/2407/9596-0 • Telefax: 0049/2407/9596-9 Internet: www.shaker.de • e-mail: [email protected] i Foreword iii Preface vii Contributors ix CHAPTER 1 1 J. E. FABER, X. DAI and J. LUCITTI CHAPTER 2 ! " # $% 23 F. LE NOBLE CHAPTER 3 $% " # & ' 39 L. C. NAPP and F. P. LIMBOURG CHAPTER 4 # & % " # ( ) 67 W. SCHAPER CHAPTER 5 & % 75 C. TROIDL, K. TROIDL, J.I. PAGEL, E. DEINDL and W. SCHAPER CHAPTER 6 !# * + , $ - .+ 89 J. L. UNTHANK, T. L. HAAS AND S. J. MILLER CHAPTER 7 # 121 T. ZIEGELHOEFFER AND E. DEINDL ii CHAPTER 8 % %0& # & 133 T. TRENKWALDER, R. HINKEL AND C. KUPATT CHAPTER 9 , " + * % 145 A.A. HELLINGMAN, L. SEGHERS, P.H.A. QUAX AND V. VAN WEEL CHAPTER 10 * "" % 155 R. HAVERSLAG, S. GRUNDMANN AND I. E. HOEFER CHAPTER 11 % 1 167 A.M. VAN DER LAAN, J.J. PIEK AND N. VAN ROYEN CHAPTER 12 - # 2 & # 179 N.
    [Show full text]